

# Galápagos

**We discover, we dare, we care**

JP Morgan Healthcare Conference | 13-16 January 2020



# Disclaimer

This presentation contains forward-looking statements, including (without limitation) statements concerning the progress of our clinical pipeline, the statements regarding the global R&D collaboration with Gilead, the amount and timing of potential future milestone, opt-in and/or royalty payments by Gilead, the slides captioned "GLPG: success story with strong fundamentals" "Pipeline with significant newsflow in 2020" "Filgotinib: potential for 5 launches in next 4 years" "Filgotinib: 2020 is major year" "European commercial footprint" "Global inflammation market \$65B by 2027" "Building an IPF/fibrosis portfolio" "Landmark Ph3 program ISABELA 1&2" "Key readouts in H2 in IPF/fibrosis" "1972 protects cartilage" timeline" "ROCCELLA Ph2b trial" "Deep early pipeline" "Novel target discovery engine," the embedded video about our target discovery approach, "Restoring the autoimmune balance" "Toledo: robust activity in *in vivo* models" "Strong financials" "Looking forward to a newsflow rich 2020" "Pioneering for patients," all slides pertaining to the collaboration with Gilead announced on 14 July 2019, statements regarding the expected timing, design and readouts of ongoing and planned clinical trials (i) with filgotinib in RA, IBD, and other potential indications (ii) with GLPG1690 and GLPG1205 in IPF and Ssc, (iii) with the Toledo program, (iv) with GLPG1972 in OA, and expectations regarding the commercial potential of our product candidates. When used in this presentation, the words "anticipate," "believe," "can," "could," "estimate," "expect," "intend," "is designed to," "may," "might," "will," "plan," "potential," "possible," "predict," "objective," "should," and similar expressions are intended to identify forward-looking statements.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Among the factors that may result in differences are the inherent uncertainties associated with competitive developments, clinical trial and product development activities, regulatory approval requirements (including that data from the company's development programs may not support registration or further development of its compounds due to safety, efficacy or other reasons), reliance on third parties (including Galapagos' collaboration partners Gilead, Servier, MorphoSys, and Novartis) and estimating the commercial potential of its product candidates. A further list and description of these risks, uncertainties and other risks can be found in Galapagos' Securities and Exchange Commission ("SEC") filing and reports, including Galapagos' most recent Form 20-F and subsequent filings with the SEC. Given these uncertainties, you are advised not to place any undue reliance on such forward-looking statements.

All statements herein speak only as of the release date of this document. Galapagos expressly disclaims any obligation to update any statement in this document to reflect any change in future development with respect thereto, any future results, or any change in events, conditions and/or circumstances, on which any statement is based, unless specifically required by law or regulation.

Under no circumstances may any copy of this presentation, if obtained, be retained, copied, or transmitted.



# GLPG: success story with strong fundamentals



## Novel MoA drugs close to market

---

***filgotinib***: Potential approvals/launches in RA

Topline Ph2+ data in all program areas in 2020



## Long term opportunities

---

>30 early programs such as ***Toledo***

Novel target ***discovery engine***



## Solid fundamentals


---

Strong financials, incl. ***€5.8B cash***


***Gilead*** collaboration



# Pipeline with significant newsflow in 2020



# Filgotinib: potential for 5 launches in next 4 years



RA: rheumatoid arthritis UC: ulcerative colitis AS: ankylosing spondylitis PsA: psoriatic arthritis



# Filgotinib, a clinically selective JAK1 inhibitor



## Strong activity

---

on signs & symptoms



## Normalization

---

of disease parameters



## Differentiated safety profile

---

infections, zoster, VTEs

---

***Consistent safety & efficacy  
data in RA, CD, PsA, AS***

# Filgotinib: 2020 is a major year



Expected start of Ph3 in AS



Potential approvals for RA, milestone payments



DIVERSITY Ph3 in CD expected to be fully recruited

2020

2021

Expected topline  
SELECTION Ph3  
in UC



Potential commercial launches in RA






# European commercial footprint

## 2020 – 2021 filgotinib

- Benelux
- France, Italy, Spain
- UK, Germany

## 2022 – 2023

- Roll out in rest of Europe
- Future products








# Global inflammation market \$65B by 2027

Estimated market size, \$B

---




RA: rheumatoid arthritis CD: Crohn's disease UC: ulcerative colitis AS: ankylosing spondylitis PsA: psoriatic arthritis

Source: Galapagos estimates, Decision Resources Group



# Building an IPF & fibrosis portfolio

Two topline in H2 '20, ISABELA futility in Q1 '21



IPF: idiopathic pulmonary fibrosis, SSc: systemic sclerosis, PCC: preclinical candidate



# Landmark Ph3 program ISABELA 1&2



- 1500 IPF patients total in two identical Phase 3 studies
- Patients remain on standard of care throughout
- Global program with US & EU component
- Primary endpoint: FVC decline at 52 weeks
- Secondary: hospitalizations, mortality, quality of life, safety/tolerability

FVC: forced vital capacity



# Key readouts in H2 in fibrosis/IPF



**30 SSc patients**

mRSS @ **24 weeks**

mRSS: modified Rodnan Skin Score



**60 IPF patients on SoC**


**FVC @ 26 weeks**

FVC: forced vital capacity




# '1972 protects cartilage


Preclinical mouse model




vehicle



'1972  
low dose



'1972  
medium dose



cartilage

'1972  
high dose



# ROCCELLA Phase 2b trial



- 850 patients with knee osteoarthritis, recruited globally
- Primary endpoint: reduction in cartilage loss at 52 weeks
- Secondary: structural & clinical parameters (incl. pain & function), safety/tolerability

FDA granted fast track status  
Fully recruited, topline expected H2 '20



# Deep, early pipeline

**30**

validated targets

---

**15**

programs in LO

---

**5**

PCCs

---

- `4471 – inflammation
- `4399 – inflammation
- `4259 – inflammation
- `4124 – fibrosis
- `4059 – metabolic

**5**

Ph1 programs

---

- `3312 – inflammation
- `3970 – inflammation
- `3667 – inflammation

- `555 – inflammation
- `2737 – kidney disease



# Novel target discovery engine



How we discover novel targets

Galápagos 





# Toledo: restoring the immune imbalance





# Toledo: robust activity in *in vivo* models

		IBD	RA	Pso	PsA	SLE	OP	Fib
PanTOL	'3312	●	●	●	●	●	●	●
TOL2/3	'3970	●	●	●	●	●	●	●
TOL3	'4399	●	●	●	●	2020	2020	2020
4 <sup>th</sup> gen	LO	2020						
5 <sup>th</sup> gen	LO	2020						

- Topline PoC in UC with '3312 in 2020
- Plan multiple PoC's with '3970 in patients in 2020

green: preclinical activity; orange: insufficient preclinical activity



## Strong financials

**€5.8B**

cash

**FY19** cash burn

**€320-340M**

**€3.1B**

deferred revenues

**€4M** accumulated

losses in **20** years



# Gilead-Galapagos collaboration

Unique *blueprint*

**10 year**

---

collaboration  
& standstill

**\$1.5B**

---

equity investment by  
Gilead

**\$3.95B**  
upfront

---

plus opt-in fees  
& milestone

**20+%**  
royalties

---

Galapagos retains  
full European rights\*

\*except filgotinib



# Looking forward to **a newsflow rich 2020**

## **Topline data:**

filgotinib Ph3 UC

`1205 Ph2 IPF

`1690 Ph2 SSc

`1972 Ph2b OA

`3312 Ph2 UC

---

## **Clinical trials:**

>80 GLPG clinical trials expected

start filgotinib Ph3 AS

start `3970 PoC studies

---

## **Potential launches:**

filgotinib in RA in US,  
Europe, Japan

---

# Pioneering for patients

We discover.

We dare.

*We care.*

